These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 36400098)
1. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098 [TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D; Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047 [TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183 [TBL] [Abstract][Full Text] [Related]
4. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838 [TBL] [Abstract][Full Text] [Related]
5. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495 [TBL] [Abstract][Full Text] [Related]
6. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B; Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291 [TBL] [Abstract][Full Text] [Related]
8. Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney. Tan VS; Correa RJM; Warner A; Ali M; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; Suk Kwon Y; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Hannan R; Staehler M; Zaorsky NG; Louie AV; Siva S Eur Urol Oncol; 2024 Dec; 7(6):1527-1534. PubMed ID: 38987159 [TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849 [TBL] [Abstract][Full Text] [Related]
10. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function. Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057 [TBL] [Abstract][Full Text] [Related]
12. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU. Bentahila R; Bensalah K; Benziane-Ouaritini N; Barthelemy P; Rioux-Leclerc N; Correas JM; Belhomme S; Bigot P; Sargos P Fr J Urol; 2024 Jul; 34(7-8):102660. PubMed ID: 38823486 [TBL] [Abstract][Full Text] [Related]
14. Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II. Gaudreault M; Hardcastle N; Jackson P; McIntosh L; Higgs B; Pryor D; Sidhom M; Dykyj R; Moore A; Kron T; Siva S Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):648-654. PubMed ID: 38679212 [TBL] [Abstract][Full Text] [Related]
15. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550 [TBL] [Abstract][Full Text] [Related]
16. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777 [TBL] [Abstract][Full Text] [Related]
18. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma. Zalay O; Mehra P; Pereira I; Malone J; Malone S World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135 [TBL] [Abstract][Full Text] [Related]
19. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship. Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma. McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]